Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be beneficial for patients with advanced cancer in phase III randomized control trials which had associated biomarker analyses. We aim to evaluate the predictive value of circulating VEGF-A on patient survival in these studies.
PubMed was searched for eligible trials from the date of inception to 31st December, 2015. Based on the median circulating level of VEGF-A in each trial, we conducted a meta-analysis with random-effect model to estimate the treatment effects between bevacizumab-based treatments and treatments without bevacizumab on progression-free survival (PFS) and overall survival (OS). Interaction test was used to examine the predictive value.
Eight studies were included, involving 4,523 patients analyzed with VEGF-A level. Patients following bevacizumab-based treatments had significantly prolonged PFS regardless of VEGF-A level (high:HR = 0.70 [95 % CI 0.63-0.77], P
There is still insufficient evidence to support the use of VEGF-A as a predictive biomarker for bevacizumab-based treatment in advanced cancers.
Clinical trial identification
Legal entity responsible for the study
The First Affiliated Hospital of Guangzhou Medical University
All authors have declared no conflicts of interest.